✦ LIBER ✦

Induction of immune tolerance by neonatal intravenous injection of human factor VIII in murine hemophilia A

✍ Scribed by S. Madoiwa; T. Yamauchi; Y. Hakamata; E. Kobayashi; M. Arai; T. Sugo; J. Mimuro; Y. Sakata

Book ID: 109155010
Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 338 KB
Volume: 2
Category: Article
ISSN: 1538-7933
DOI: 10.1111/j.1538-7933.2004.00671.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Induction of factor VIII-specific unresp

Induction of factor VIII-specific unresponsiveness by intrathymic factor VIII injection in murine hemophilia A

✍ S. MADOIWA; T. YAMAUCHI; E. KOBAYASHI; Y. HAKAMATA; M. DOKAI; N. MAKINO; Y. KASH 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 659 KB

Factor VIII gene (F8) mutations as predi

Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors

✍ A. COPPOLA; M. MARGAGLIONE; E. SANTAGOSTINO; A. ROCINO; E. GRANDONE; P. M. MANNU 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB

Mechanisms of action of immune tolerance

Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors

✍ Birgit M. Reipert; Pauline M. W. Van Den Helden; Hans-Peter Schwarz; Christina H 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 703 KB

Domain specificity of factor VIII inhibi

Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A

✍ P. M. W. VAN HELDEN; P. H. P. KAIJEN; E. P. MAUSER-BUNSCHOTEN; K. FISCHER; H. M. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 410 KB

Phosphatidylserine containing liposomes

Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A

✍ Karthik Ramani; Razvan D. Miclea; Vivek S. Purohit; Donald E. Mager; Robert M. S 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 257 KB

Factor VIII (FVIII) is a multidomain protein that is deficient in hemophilia A, a clinically important bleeding disorder. Replacement therapy using recombinant human FVIII (rFVIII) is the main therapy. However, approximately 15-30% of patients develop inhibitory antibodies that neutralize rFVIII act

Successful induction of immune tolerance

Successful induction of immune tolerance by continuous infusion of recombinant factor VIII in a haemophilia A patient with high-inhibitor titres

✍ K. TAMURA; T. KANAZAWA; M. SUZUKI; A. SHIOYA; A. MORIKAWA 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB